Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies

Jacob Beiriger
* ORCID logo ,
Kashyap Chauhan
ORCID logo ,
Adnan Khan
* ,
Taha Shahzad
,
Natalia Salinas
,
Peter Zhang
,
Sarah Chen
,
Anh Nguyen
,
Brian Yan
,
John Bruckbauer
,
Dina Halegoua-DeMarzio
ORCID logo
Version 1 : Received: 14 August 2023 / Approved: 15 August 2023 / Online: 15 August 2023 (12:51:25 CEST)

A peer-reviewed article of this Preprint also exists.

Beiriger, J.; Chauhan, K.; Khan, A.; Shahzad, T.; Parra, N.S.; Zhang, P.; Chen, S.; Nguyen, A.; Yan, B.; Bruckbauer, J.; Halegoua-DeMarzio, D. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies. Livers 2023, 3, 637-656. Beiriger, J.; Chauhan, K.; Khan, A.; Shahzad, T.; Parra, N.S.; Zhang, P.; Chen, S.; Nguyen, A.; Yan, B.; Bruckbauer, J.; Halegoua-DeMarzio, D. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies. Livers 2023, 3, 637-656.

Abstract

This paper provides a comprehensive review of the current understanding of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH), focusing on key factors influencing its pathogenesis and emerging therapeutic strategies. The background highlights the growing prevalence of NAFLD and NASH, emphasizing their multifactorial nature. The methods section outlines the various contributors to NAFLD development, including genetic, dietary, and environmental factors. The results highlight the intricate interplay between these factors and their impact on hepatic lipid metabolism, inflammation, and insulin resistance. Genetic predisposition, dietary fat intake, and excessive fructose consumption are discussed as significant contributors to NAFLD progression. The conclusions emphasize the lack of a single therapeutic approach and underscore the need for combination strategies. Lifestyle interventions, particularly weight loss through diet and exercise, remain crucial, while pharmacological options like GLP-1 receptor agonists, obeticholic acid, lanifibranor, and resmetirom show promise but require further validation. Bariatric surgery and emerging endoscopic procedures offer potential in eligible patients. In sum, this review underscores the complexity of NAFLD and NASH, advocating for a multifaceted approach to address this increasingly prevalent and clinically relevant condition.

Keywords

NAFLD; NASH; pathogenesis; genetic factors; dietary factors; environmental factors; therapeutic strategies

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.